Ultragenyx Pharmaceutical Inc [RARE] stock prices are down -0.75% to $39.61 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RARE shares have gain 8.46% over the last week, with a monthly amount glided 8.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman upgraded its rating to Buy on June 06, 2024, and elevated its price target to $67. On April 22, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $77 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $72 on December 08, 2023. Evercore ISI upgraded its rating to Outperform for this stock on June 06, 2023, and upped its price target to $80. In a note dated April 26, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $114 on this stock.
The stock price of Ultragenyx Pharmaceutical Inc [RARE] has been fluctuating between $29.59 and $60.37 over the past year. Currently, Wall Street analysts expect the stock to reach $89.5 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $39.61 at the most recent close of the market. An investor can expect a potential return of 125.95% based on the average RARE price forecast.
Analyzing the RARE fundamentals
The Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 590.69M for trailing twelve months, representing a surge of 27.99%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.87%, Pretax Profit Margin comes in at -0.93%, and Net Profit Margin reading is -0.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.86 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.08 points at the first support level, and at 38.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.97, and for the 2nd resistance point, it is at 40.32.
Ratios To Look Out For
It’s worth pointing out that Ultragenyx Pharmaceutical Inc [NASDAQ:RARE]’s Current Ratio is 2.40. Further, the Quick Ratio stands at 2.24, while the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 6.34, the price to book ratio is 25.74.
Transactions by insiders
Recent insider trading involved Sanders Corazon (Corsee) D., Director, that happened on Jun 20 ’25 when 2405.0 shares were sold. Director, CORAZON D. SANDERS completed a deal on Jun 20 ’25 to buy 2405.0 shares. Meanwhile, EVP and Chief Medical Officer Crombez Eric sold 520.0 shares on May 05 ’25.
